vimarsana.com

Page 5 - Real Time Polymerase Chain Reaction Based News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mainz Biomed Announces the Closing of its $25 8 Million

Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission.

United statesMainz biomedOrtoli rosenstadtBoustead securitiesEquity capital marketsReal time polymerase chain reaction basedNasdaq mynzMainz biomed nv

Mainz Biomed Appoints Steve Quinn as VP Business Development - Press Release

BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2022 (GLOBE NEWSWIRE) Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular

United statesUnited kingdomMainz biomedMainz biomed coloalertGuido baechlerExchange commissionVp business developmentEuropean unionAmerican cancer societyBusiness developmentSteve quinnVice presidentChief executive officerMiddle eastReal time polymerase chain reaction basedPrivate securities litigation reform act

Mainz Biomed Announces Pricing of Follow-on Offering

BERKELEY, Calif. and MAINZ, Germany, Jan. 26, 2022 (GLOBE NEWSWIRE) Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular.

United statesMainz biomedExchange commissionOrtoli rosenstadtBoustead securitiesFollow on offeringOffering priceEquity capital marketsReal time polymerase chain reaction basedNasdaq mynzMainz biomed nv

Mainz Biomed Appoints Michele Pedrocchi, Former Head of

BERKELEY, Calif. and MAINZ, Germany, Jan. 12, 2022 (GLOBE NEWSWIRE) Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular.

United statesMichele pedrocchiMainz biomedGuido baechlerBusiness development for diagnosticsEuropean unionAmerican cancer societyStrategic advisoryStrategic advisory boardChief executive officerGlobal headBusiness developmentCompanion diagnosticsIndependent strategic advisorNon executive directorReal time polymerase chain reaction based

Mainz Biomed to Present at the H C Wainwright Bioconnect Virtual Conference

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2022 Mainz Biomed N.V. , a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido. | January 11, 2022

United statesHc wainwright bioconnectMainz biomedGuido baechlerExchange commissionEuropean unionAmerican cancer societyGlobenewswire incChief executive officerBioconnect virtual conferenceCancer societyReal time polymerase chain reaction basedPrivate securities litigation reform actMainz biomedbv stock exchangePress releaseHat mynz nl0015000lc2

vimarsana © 2020. All Rights Reserved.